The U.S.-backed program previously supported “investments in HIV testing, counselling, community-based organizations and other key health system intervention.”
It's a twice-a-year injection that is remarkably effective in preventing an HIV infection. Distribution is starting. But questions are being raised about getting it to the areas that need it most.
AI:The distribution of lenacapavir, a highly effective twice-yearly injection designed to prevent HIV infection, has begun, though its rollout faces criticism regarding the logistics and equity of reaching high-need populations in regions like Uganda. This development follows a broader pattern of scrutiny surrounding pharmaceutical interventions and global health mandates, particularly as previous reports have highlighted concerns over vaccine safety, medical misinformation, and the influence of Big Pharma on clinical practices.Open
‘This is a perfect setup for an explosion of a sexually transmitted disease.’
The United Nations has set a goal for near universal HIV diagnosis and treatment for all by 2030. No country in Asia has hit the mark — until this year.
Dr. Kenneth Ngure, president-elect of the International AIDS Society, says. "We have had very good scientific advances ... yet the funding cuts have also taken us back."
‘Sex work or starve.”
New research also shows that children and high-risk adult populations have been particularly affected.
According to an unsigned statement from the State Department, the U.S. will phase out support for H.I.V. prevention and treatment in South Africa.
Three brothers say their mother and father died after losing access to their HIV medications. Now the boys are figuring out how to navigate life.